Shares of Day One Biopharmaceuticals, Inc. (DAWN) have gained 2.3% over the past four weeks to close the last trading session at $7.04, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$23.56 indicates a potential upside of 234.7%.The average comprises nine short-term price targets ranging from a low of $16.00 to a high of$34.00, with a standard deviation of $5.68. While the low ...